Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality | Breast Cancer | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
King MC, Marks JH, Mandell JB.New York Breast Cancer Study Group.  Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 Science. 2003;302(5645):643-64614576434PubMedGoogle ScholarCrossref
Struewing JP, Hartge P, Wacholder S,  et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.  N Engl J Med. 1997;336(20):1401-14089145676PubMedGoogle ScholarCrossref
Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance.  J Clin Oncol. 2007;25(11):1329-133317416853PubMedGoogle ScholarCrossref
Ford D, Easton DF, Stratton M,  et al; The Breast Cancer Linkage Consortium.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families.  Am J Hum Genet. 1998;62(3):676-6899497246PubMedGoogle ScholarCrossref
Anglian Breast Cancer Study Group.  Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases.  Br J Cancer. 2000;83(10):1301-130811044354PubMedGoogle ScholarCrossref
Satagopan JM, Boyd J, Kauff ND,  et al.  Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.  Clin Cancer Res. 2002;8(12):3776-378112473589PubMedGoogle Scholar
Rebbeck TR, Lynch HT, Neuhausen SL,  et al; Prevention and Observation of Surgical End Points Study Group.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.  N Engl J Med. 2002;346(21):1616-162212023993PubMedGoogle ScholarCrossref
Rebbeck TR, Levin AM, Eisen A,  et al.  Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.  J Natl Cancer Inst. 1999;91(17):1475-147910469748PubMedGoogle ScholarCrossref
Kauff ND, Satagopan JM, Robson ME,  et al.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.  N Engl J Med. 2002;346(21):1609-161512023992PubMedGoogle ScholarCrossref
Finch A, Beiner M, Lubinski J,  et al; Hereditary Ovarian Cancer Clinical Study Group.  Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation.  JAMA. 2006;296(2):185-19216835424PubMedGoogle ScholarCrossref
Kramer JL, Velazquez IA, Chen BE,  et al.  Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers.  J Clin Oncol. 2005;23(34):8629-863516314625PubMedGoogle ScholarCrossref
Domchek SM, Friebel TM, Neuhausen SL,  et al.  Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers.  Lancet Oncol. 2006;7(3):223-22916510331PubMedGoogle ScholarCrossref
Chang-Claude J, Andrieu N, Rookus M,  et al.  Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study.  Cancer Epidemiol Biomarkers Prev. 2007;16(4):740-74617416765PubMedGoogle ScholarCrossref
Eisen A, Lubinski J, Klijn J,  et al.  Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers.  J Clin Oncol. 2005;23(30):7491-749616234515PubMedGoogle ScholarCrossref
Kauff ND, Domchek SM, Friebel TM,  et al.  Risk-reducing salpingo-oophorectomy for the prevention of BRCA1 - and BRCA2 -associated breast and gynecologic cancer.  J Clin Oncol. 2008;26(8):1331-133718268356PubMedGoogle ScholarCrossref
Rutter JL, Wacholder S, Chetrit A,  et al.  Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations.  J Natl Cancer Inst. 2003;95(14):1072-107812865453PubMedGoogle ScholarCrossref
Shah P, Rosen M, Stopfer J,  et al.  Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers.  Breast Cancer Res Treat. 2009;118(3):539-54619609668PubMedGoogle ScholarCrossref
Lin DYWL. Robust inferences for the Cox proportional hazards model.  J Am Stat Assoc. 1989;84:1074-1078Google ScholarCrossref
Kauff ND, Barakat RR. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2 J Clin Oncol. 2007;25(20):2921-292717617523PubMedGoogle ScholarCrossref
Meijers-Heijboer H, van Geel B, van Putten WL,  et al.  Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.  N Engl J Med. 2001;345(3):159-16411463009PubMedGoogle ScholarCrossref
Rebbeck TR, Friebel T, Lynch HT,  et al.  Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers.  J Clin Oncol. 2004;22(6):1055-106214981104PubMedGoogle ScholarCrossref
Parker WH, Jacoby V, Shoupe D, Rocca W. Effect of bilateral oophorectomy on women's long-term health.  Womens Health (Lond Engl). 2009;5(5):565-57619702455PubMedGoogle ScholarCrossref
Parker WH, Manson JE. Oophorectomy and cardiovascular mortality: is there a link?  Menopause. 2009;16(1):1-218971791PubMedGoogle ScholarCrossref
Rocca WA, Bower JH, Maraganore DM,  et al.  Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause.  Neurology. 2007;69(11):1074-108317761551PubMedGoogle ScholarCrossref
Rocca WA, Bower JH, Maraganore DM,  et al.  Increased risk of parkinsonism in women who underwent oophorectomy before menopause.  Neurology. 2008;70(3):200-20917761549PubMedGoogle ScholarCrossref
Parker WH, Broder MS, Chang E,  et al.  Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses' Health Study.  Obstet Gynecol. 2009;113(5):1027-103719384117PubMedGoogle Scholar
Fisher B, Jeong JH, Bryant J,  et al.  Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer.  Lancet. 2004;364(9437):858-86815351193PubMedGoogle ScholarCrossref
Davidson NE, O’Neill AM, Vukov AM,  et al.  Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer.  J Clin Oncol. 2005;23(25):5973-598216087950PubMedGoogle ScholarCrossref
Metcalfe K, Lynch HT, Ghadirian P,  et al.  Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.  J Clin Oncol. 2004;22(12):2328-233515197194PubMedGoogle ScholarCrossref
Pierce LJ, Levin AM, Rebbeck TR,  et al.  Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2 -associated stage I/II breast cancer.  J Clin Oncol. 2006;24(16):2437-244316636335PubMedGoogle ScholarCrossref
Lakhani SR, Van De Vijver MJ, Jacquemier J,  et al.  The pathology of familial breast cancer.  J Clin Oncol. 2002;20(9):2310-231811981002PubMedGoogle ScholarCrossref
Rocca WA, Grossardt BR, de Andrade M,  et al.  Survival patterns after oophorectomy in premenopausal women.  Lancet Oncol. 2006;7(10):821-82817012044PubMedGoogle ScholarCrossref
Rossouw JE, Prentice RL, Manson JE,  et al.  Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.  JAMA. 2007;297(13):1465-147717405972PubMedGoogle ScholarCrossref
Manson JE, Allison MA, Rossouw JE,  et al.  Estrogen therapy and coronary-artery calcification.  N Engl J Med. 2007;356(25):2591-260217582069PubMedGoogle ScholarCrossref
Rebbeck TR, Friebel T, Wagner T,  et al.  Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.  J Clin Oncol. 2005;23(31):7804-781016219936PubMedGoogle ScholarCrossref
Klaren HM, van't Veer LJ, van Leeuwen FE, Rookus MA. Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation.  J Natl Cancer Inst. 2003;95(13):941-94712837830PubMedGoogle ScholarCrossref
Hartmann LC, Degnim A, Schaid DJ. Prophylactic mastectomy for BRCA1/2 carriers.  J Clin Oncol. 2004;22(6):981-98314981099PubMedGoogle ScholarCrossref
Evans DG, Baildam AD, Anderson E,  et al.  Risk reducing mastectomy.  J Med Genet. 2009;46(4):254-25818996907PubMedGoogle ScholarCrossref
Original Contribution
September 1, 2010

Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality

Author Affiliations

Author Affiliations: Abramson Cancer Center (Drs Domchek and Rebbeck), Department of Medicine (Dr Domchek), and Center for Clinical Epidemiology and Biostatistics (Ms Friebel and Dr Rebbeck), University of Pennsylvania School of Medicine, Philadelphia; Division of Special Gynecology, Medical University of Vienna, Vienna, Austria (Dr Singer); Department of Clinical Genetics, St Mary's Hospital, Manchester, England (Dr Evans); Department of Preventive Medicine, Creighton University, Omaha, Nebraska (Dr Lynch); Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC (Dr Isaacs); Dana Farber Cancer Institute, Boston, Massachusetts (Dr Garber); Epidemiology Division, School of Medicine, University of California, Irvine (Dr Neuhausen); Cancer Genetic Counseling Program, Yale University, New Haven, Connecticut (Ms Matloff); Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, England (Dr Eeles); Guys and St Thomas Foundation Trust, London, England (Dr Pichert); Netherlands Cancer Institute, Amsterdam, the Netherlands (Dr Van t’veer); Beth Israel Deaconess Medical Center, Boston, Massachusetts (Dr Tung); City of Hope National Medical Center, Duarte, California (Dr Weitzel); Mayo Clinic College of Medicine, Rochester, Minnesota (Dr Couch); NorthShore University HealthSystem, Evanston, Illinois (Dr Rubinstein); University of Chicago Medical Center, Chicago, Illinois (Drs Rubinstein and Olopade); Jonsson Comprehensive Cancer Center, University of California, Los Angeles (Dr Ganz); Fox Chase Cancer Center, Philadelphia, Pennsylvania (Dr Daly); Division of Hematology and Oncology, University of Texas Health Science Center, San Antonio (Dr Tomlinson); Department of Community and Family Medicine, Duke University Medical Center, Durham, North Carolina (Dr Schildkraut); and Baylor-Charles A. Sammons Cancer Center, Dallas, Texas (Dr Blum).

JAMA. 2010;304(9):967-975. doi:10.1001/jama.2010.1237

Context Mastectomy and salpingo-oophorectomy are widely used by carriers of BRCA1 or BRCA2 mutations to reduce their risks of breast and ovarian cancer.

Objective To estimate risk and mortality reduction stratified by mutation and prior cancer status.

Design, Setting, and Participants Prospective, multicenter cohort study of 2482 women with BRCA1 or BRCA2 mutations ascertained between 1974 and 2008. The study was conducted at 22 clinical and research genetics centers in Europe and North America to assess the relationship of risk-reducing mastectomy or salpingo-oophorectomy with cancer outcomes. The women were followed up until the end of 2009.

Main Outcomes Measures Breast and ovarian cancer risk, cancer-specific mortality, and overall mortality.

Results No breast cancers were diagnosed in the 247 women with risk-reducing mastectomy compared with 98 women of 1372 diagnosed with breast cancer who did not have risk-reducing mastectomy. Compared with women who did not undergo risk-reducing salpingo-oophorectomy, women who underwent salpingo-oophorectomy had a lower risk of ovarian cancer, including those with prior breast cancer (6% vs 1%, respectively; hazard ratio [HR], 0.14; 95% confidence interval [CI], 0.04-0.59) and those without prior breast cancer (6% vs 2%; HR, 0.28 [95% CI, 0.12-0.69]), and a lower risk of first diagnosis of breast cancer in BRCA1 mutation carriers (20% vs 14%; HR, 0.63 [95% CI, 0.41-0.96]) and BRCA2 mutation carriers (23% vs 7%; HR, 0.36 [95% CI, 0.16-0.82]). Compared with women who did not undergo risk-reducing salpingo-oophorectomy, undergoing salpingo-oophorectomy was associated with lower all-cause mortality (10% vs 3%; HR, 0.40 [95% CI, 0.26-0.61]), breast cancer–specific mortality (6% vs 2%; HR, 0.44 [95% CI, 0.26-0.76]), and ovarian cancer–specific mortality (3% vs 0.4%; HR, 0.21 [95% CI, 0.06-0.80]).

Conclusions Among a cohort of women with BRCA1 and BRCA2 mutations, the use of risk-reducing mastectomy was associated with a lower risk of breast cancer; risk-reducing salpingo-oophorectomy was associated with a lower risk of ovarian cancer, first diagnosis of breast cancer, all-cause mortality, breast cancer–specific mortality, and ovarian cancer–specific mortality.